Arrhythmias & electrophysiology

Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation

Eur Heart JPublished Prospective registry study with network meta-analysis and cost analysis

Authors' conclusion

Left atrial appendage closure in NVAF in a real-world setting may result in lower stroke and major bleeding rates than reported in LAAC clinical trials. Left atrial appendage closure in both settings achieves cost parity in a relatively short period of time and may offer substantial savings compared with current therapies. Savings are most pronounced among higher risk patients and those unsuitable for anticoagulation.

Study context

Population
Patients with non-valvular atrial fibrillation (NVAF) at risk of stroke, suitable and unsuitable for long-term anticoagulation (age 71.3 ± 9.2 years, CHA2DS2-VASc 4.5 ± 1.6, HAS-BLED 3.8 ± 1.1)
Participants
110 patients · 2 centres
Comparison
Left atrial appendage closure (LAAC) (Watchman) vs warfarin, dabigatran, rivaroxaban, apixaban, aspirin and no treatment
  • Registry LAACn = 110
Outcome
Annual event rates in registry LAAC
Follow-up
24.1 ± 4.6 months
Methodological detailstwo centres, 10-year horizon, sensitivity analyses
  • Two centres
  • 10-year horizon
  • Sensitivity analyses

Pooled result

As reported in the abstract

Mean absolute difference

0.89%

P = 0.02

stroke, lower in registry

Mean absolute difference

5.48%

P < 0.001

major bleeding, lower in registry

Annual stroke rate
0.9% (2/223 patient-years)
Annual major bleeding rate
0.9% (2/223 patient-years)
Annual all-cause mortality
1.8% (4/223 patient-years)

Further pooled results

Procedural success

Procedural success rate
92% (103/112)

Anticoagulant therapy stopped in implanted patients · 12 months

Anticoagulant therapy successfully stopped
91.2% (93/102)

Costs (10-year horizon)

Cost parity vs dabigatran 110 mg
4.9 years
Cost parity vs warfarin
8.4 years
LAAC cost-saving against all therapies at 10 years
£1162-£7194

Original publication

Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation. Eur Heart J. Published 1 March 2016. doi:10.1093/eurheartj/ehw048

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.